LABORATORY REF. NO.

520804/A
PYN407 - TTYT DONG XUAN - Biosystems A25

PYN407

MONTHLY CLINICAL CHEMISTRY

CYCLE 17 SAMPLE 11

Explanation of codes used in this report

R - Results removed due to reconstitution error

N - No result returned
C - Result corrected

Authorised by: Stephen Doherty, RIQAS Manager Issue No: 1 Issue Date: 03/12/2020

BÔ. Y TÊ´
ÐAI ´ `
. HOC . Y DUOC . THÀNH PHÔ HÔ CHÍ MINH
, ,

A
?

TRUNG TÂM KIÊM CHUÂN CHÂT

?
´ LUONG XÉT NGHIÊM . Y HOC
, ,
. .
Ðia
. ch
?
1 : ´
sô 131 Nguyên
~
Chí Thanh, Phuong
,
`
,
9, Quân
. 5, TPHCM.
Email1: TRUNGTAMKIEMCHUAN@GMAIL.COM

A
Email2: EQA.QCC.UMP@GMAIL.COM
Website: WWW.QCCUMP.COM
Page 1
Ðiên
. thoai:
. 028.38531058 - Fax: 028.38531049
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

I 135.719

I 155.133

I 153.570

I 149.596

I 151.025

I 155.120

I 150.454

I 139.515
I 13.151

I 35.340

I 39.341

I 40.335

I 39.251

I 41.289

I 13.193

I 39.747

I 39.615

I 39.538

I 42.153

I 12.705
ALT (GPT), U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5953 125.665 7.6 0.15 11.69 476

Tris buffer without P5P 4474 124.038 7.7 0.18 11.54 401 +11

Standard Deviation
Biosystems A25 50 139.515 7.5 1.85 12.98 8
0

-1
Your Result 153.000 SDI 1.04
RMSDI Too Few
-2

Mean for Comparison 139.515 TS 70

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV 9.7 Sample Number

RM%DEV Too Few TDPA = 15.3%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 15.30 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number
800

700
>= 20

15
600
Number of Laboratories

10

500
5
% Deviation

400
0

300 -5

200 -10

-15
100

<= -20

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 100.65 107.80 114.94 122.09 129.23 136.38 143.52 150.67 >
U/l
>= 20

15
Method N Mean CV% Um
10
Tris buffer without P5P 4474 124.038 7.7 0.18
Tris buffer with P5P 455 130.623 6.3 0.48
5
Beckman Mod. IFCC Ref. without P5P 441 128.605 3.7 0.28
% Deviation

Siemens/Dade standard nonIFCC correlated 162 134.671 3.9 0.51

Ortho Vitros MicroSlide Systems 114 131.592 4.0 0.62 0

Ortho Vitros MicroSlide visible 45 129.964 3.5 0.85

Agappe - IFCC 44 132.571 9.6 2.40 -5
Colorimetric 34 117.209 6.3 1.58
Beckman IFCC Ref. with P5P 29 132.099 4.5 1.39
-10
Other Dry Chemistry 25 124.436 5.8 1.80
Phosphate buffer, DGKC 27 123.171 12.0 3.54
Tris buffer, SCE 23 122.415 10.3 3.29 -15

Tris buffer with P5P, NVKC 16 128.788 17.5 7.03

Beckman (Extinction Coefficient) 2 123.850 11.2 12.31 <= -20

0 20 40 60 80 100 120 140 160

Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 2

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

M 163.917
M 43.706

M 16.825
I 186.813

I 166.117

I 159.433

I 171.278

I 164.979

I 184.567

I 160.183
I 11.593

I 35.738

I 40.120

I 38.178

I 38.679

I 38.466

I 14.584

I 40.847

I 38.875

I 37.545
AST (GOT), U/l @ 37°C
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5786 135.025 8.9 0.20 11.90 622

Tris buffer with P5P 405 163.917 10.9 1.11 14.45 23 +11

Standard Deviation
Biosystems A25 2 140.200 7.9 9.75 15.74a 0
0

-1
Your Result 148.000 SDI -1.10
RMSDI Too Few
-2

Mean for Comparison 163.917 TS 67

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV -9.7 Sample Number

RM%DEV Too Few TDPA = 14.5%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 14.50 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number

1000 >= 20

15

800
Number of Laboratories

10

5
600
% Deviation

400 -5

-10

200
-15

<= -20

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 103.36 112.41 121.45 130.50 139.54 148.59 157.63 166.68 >
U/l
>= 20

15
Method N Mean CV% Um
10
Tris buffer without P5P 4514 132.348 6.7 0.16
Beckman Mod. IFCC Ref. without P5P 434 140.256 3.6 0.30
5
Tris buffer with P5P 405 163.917 10.9 1.11
% Deviation

Siemens/Dade standard non IFCC corr. 168 170.946 4.5 0.74

Ortho Vitros MicroSlide visible 160 172.436 4.6 0.79 0

Agappe - IFCC 43 138.436 7.3 1.94

Colorimetric 38 127.905 8.7 2.26 -5
Other Dry Chemistry 26 141.308 10.6 3.67
Phosphate buffer, DGKC 25 133.813 8.3 2.79
-10
Tris buffer, SCE 21 133.024 6.7 2.43
Beckman IFCC Ref. with P5P 22 157.368 12.8 5.38
Tris buffer with P5P, NVKC 11 143.095 9.9 5.33 -15

Beckman (Extinction Coefficient) 5 131.520 8.7 6.37

<= -20

0 20 40 60 80 100 120 140 160

Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 3

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

Cholesterol, mmol/l

I 2.741

I 6.770

I 3.901

I 7.338

I 4.067

I 3.999

I 7.062

I 4.252

I 4.060

I 7.229

I 3.155

I 4.095

I 7.176

I 4.128

I 7.700

I 4.124

I 7.228

I 4.187

I 3.141

I 7.158
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5632 6.963 4.3 0.00 0.38 481

Cholesterol Oxidase - Abell Kendall 4535 6.993 4.1 0.01 0.38 408 +11

Standard Deviation
Biosystems A25 50 7.158 4.1 0.05 0.39 7
0

-1
Your Result 7.080 SDI -0.20
RMSDI Too Few
-2

Mean for Comparison 7.158 TS 120

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV -1.1 Sample Number

RM%DEV Too Few TDPA = 9%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 9.00 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number
800

>= 10
700

600
6
Number of Laboratories

4
500

2
% Deviation

400
0

-2
300

-4

200
-6

100 -8

<= -10

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 6.17 6.40 6.62 6.85 7.07 7.29 7.52 7.74 >
mmol/l
>= 10

Method N Mean CV% Um

6

Cholesterol Oxidase - Abell Kendall 4535 6.993 4.1 0.01 4

Cholesterol Oxidase - IDMS 539 6.979 4.0 0.02
Siemens Dimension 239 6.576 2.8 0.02 2
% Deviation

Ortho Vitros MicroSlide Systems 160 6.692 3.3 0.02

Cholesterol Dehydrogenase 68 7.026 5.0 0.05 0

Agappe - CHOD-PAP 41 6.874 4.5 0.06

Other Dry Chemistry 29 6.764 3.8 0.06 -2

-4

-6

-8

<= -10

0 1 2 3 4 5 6 7 8 9

Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 4

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

I 510.625

I 134.170

I 335.415

I 125.628

I 129.805

I 351.105

I 129.246

I 129.242

I 337.282

I 125.579

I 333.136

I 125.564

I 516.997

I 123.467

I 340.589
I 79.378

I 81.385

M 0.132

M 0.073

M 0.354
Creatinine, mmol/l
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 6021 0.365 6.2 0.00 0.03 500

Alkaline picrate with deproteinisation 146 0.354 6.0 0.00 0.03 20 +11

Standard Deviation
Biosystems A25 2 0.364 0.7 0.00 0.03 2
0

-1
Your Result 10.945 SDI 396.59
RMSDI Too Few
-2

Mean for Comparison 0.354 TS 10

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV 999.0 Sample Number

RM%DEV Too Few TDPA = 12.4%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 12.40 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number

800
>=

700 1137

600
Number of Laboratories

637

500
% Deviation

137

400

300 -363

200
-863

100

<= -1363

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 0.30 0.32 0.33 0.35 0.37 0.39 0.40 0.42 >
mmol/l
>=
1137

Method N Mean CV% Um

637
Alkaline picrate no deproteinisation 1915 0.361 7.8 0.00
Jaffe rate blanked 1408 0.353 6.2 0.00
Jaffe rate blanked comp. (-26umol/l) 649 0.375 3.6 0.00
% Deviation

Jaffe rate comp. (-18umol/l) 437 0.367 3.6 0.00 137

Roche Creatinine Plus 283 0.378 3.1 0.00

Enzymatic UV method (340nm) 257 0.374 4.2 0.00
Creatinine PAP method 253 0.371 5.6 0.00 -363
IDMS traceable 192 0.374 4.2 0.00
Other enzymatic methods 153 0.380 4.1 0.00
Alkaline picrate with deproteinisation 146 0.354 6.0 0.00
Vitros, IDMS traceable 144 0.380 3.7 0.00 -863

Jaffe rate blanked comp. (-33umol/l) 62 0.351 5.2 0.00

Other Dry Chemistry 36 0.365 5.8 0.00
Agappe - JAFFE'S KINETIC 26 0.345 4.5 0.00 <= -1363

Agappe - ENZYMATIC 16 0.347 8.3 0.01 0.00 0.05 0.10 0.15 0.20 0.25 0.30 0.35
Vitros DT60/DT60 II/DTSC II 14 0.385 6.7 0.01
Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 5

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

I 19.766

I 15.397

I 15.553

I 15.379

I 15.132

I 19.755

I 15.195

I 14.983
Glucose, mmol/l

I 2.290

I 6.175

I 6.221

I 6.157

I 6.326

I 6.130

I 2.022

I 6.175

I 5.965

I 5.910

I 6.176

I 2.274
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 6019 14.976 3.8 0.01 0.75 573

Glucose oxidase 2644 14.981 5.1 0.02 0.75 258 +11

Standard Deviation
Biosystems A25 60 14.983 4.3 0.10 0.75 7
0

-1
Your Result 14.300 SDI -0.91
RMSDI Too Few
-2

Mean for Comparison 14.983 TS 75

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV -4.6 Sample Number

RM%DEV Too Few TDPA = 8.2%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 8.20 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number

900
>= 30

800

20
700
Number of Laboratories

600
10
% Deviation

500
0

400

-10
300

200
-20

100

<= -30

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 13.48 13.90 14.33 14.76 15.18 15.61 16.04 16.47 >
mmol/l
>= 30

Method N Mean CV% Um 20

Hexokinase 3072 15.001 2.7 0.01

Glucose oxidase 2644 14.981 5.1 0.02 10

Ortho Vitros MicroSlide Systems 163 13.983 2.7 0.04

% Deviation

Glucose dehydrogenase 62 14.872 3.5 0.08

Agappe - GOD-PAP 41 15.054 4.3 0.13 0

GOD/02-Beckman method 22 14.902 2.0 0.08

Other Dry Chemistry 22 14.220 4.4 0.17
Oxygen electrode 15 14.769 2.1 0.10 -10

-20

<= -30

0 2 4 6 8 10 12 14 16 18 20

Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 6

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

I 373.182

I 255.646

I 243.785

I 252.121

I 102.043

I 241.434

I 373.511

I 246.534

I 247.203
I 29.805

I 97.162

I 97.071

I 95.158

I 91.400

I 96.980

I 25.686

I 96.770

I 95.545

I 91.399

I 23.678
Trig Total, mg/dl
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5304 249.421 4.4 0.19 20.32 642

Lipase/GPO-PAP no correction 4048 249.300 4.1 0.19 20.30 459 +11

Standard Deviation
Biosystems A25 42 247.203 5.0 2.35 20.13 9
0

-1
Your Result 2.750 SDI -12.14
RMSDI Too Few
-2

Mean for Comparison 247.203 TS 10

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV -98.9 Sample Number

RM%DEV Too Few TDPA = 13.4%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 13.40 % 80

70

Target Score
SDI in bottom 5% of peer group 60

TS & %DEV outside limits 50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number

900
>= 150

800

100
700
Number of Laboratories

600
50

500
% Deviation

400

-50
300

200
-100

100

<= -150

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 220.29 228.61 236.93 245.25 253.58 261.90 270.22 278.55 >
mg/dl
>= 150

Method N Mean CV% Um 100

Lipase/GPO-PAP no correction 4048 249.300 4.1 0.19

Lipase/GK UV. no correction 445 248.873 3.5 0.51 50

Lipase/Glycerol Dehydrogenase 267 248.905 4.0 0.76

% Deviation

Lipase/GPO-PAP, 0.11mmol/l correction 264 249.750 4.2 0.80

Ortho Vitros MicroSlide Systems 153 293.855 3.5 1.03 0

Lipase/GK UV., 0.11 mmol/l correction 70 246.694 2.9 1.08

Agappe - GPO - TOPS 36 241.771 4.9 2.46
Other Dry Chemistry 23 311.034 9.6 7.79 -50

Siemens Dimension 20 247.931 2.9 2.04

Vitros DT60/DT60 II/DTSC II 2 202.500 64.6 115.62
-100

<= -150

10 60 110 160 210 260 310 360

Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 7

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

I 23.548

I 18.622

I 19.602

I 18.575

I 18.389

I 22.135

I 18.701

I 17.280
Urea, mmol/l

I 2.303

I 6.730

I 6.820

I 7.052

I 7.069

I 6.664

I 2.322

I 7.024

I 6.877

I 6.836

I 7.013

I 2.266
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5824 18.252 5.0 0.02 1.32 553

Urease, kinetic 5135 18.298 4.8 0.02 1.32 484 +11

Standard Deviation
Biosystems A25 50 17.280 7.3 0.22 1.25 5
0

-1
Your Result 16.600 SDI -0.54
RMSDI Too Few
-2

Mean for Comparison 17.280 TS 98

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV -3.9 Sample Number

RM%DEV Too Few TDPA = 11.9%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 11.90 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number
1000

>= 20

800 15
Number of Laboratories

10

600
5
% Deviation

400
-5

-10

200
-15

<= -20

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 15.83 16.52 17.21 17.90 18.59 19.28 19.97 20.66 >
mmol/l
>= 20

15
Method N Mean CV% Um
10
Urease, kinetic 5135 18.298 4.8 0.02
Urease, end point 319 18.269 6.6 0.08
5
Ortho Vitros MicroSlide Systems 157 17.228 2.8 0.05
% Deviation

Urease, hypochlorite 107 17.859 6.6 0.14

Agappe - UREASE GLDH 38 17.526 6.1 0.22 0

Beckman - Conductivity 25 18.284 2.9 0.13

Other Dry Chemistry 21 18.572 5.0 0.25 -5
Agappe - BERTHELOT 5 17.895 3.5 0.35
Diacetyl monoxime 4 17.569 1.0 0.11
-10
O-Phthalaldehyde 4 19.220 9.9 1.18

-15

<= -20

0 5 10 15 20

Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 8

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020
Mean for Comparison

M 549.103

M 547.304

M 197.315

M 347.702

M 543.830
I 230.300

I 526.300

I 357.900

I 590.480

I 401.700

I 429.960

I 373.600

I 394.860

I 348.688

I 585.248

I 320.470

I 516.772

I 399.395

I 218.919

I 594.035
Uric Acid (Urate), umol/l
>+3

N Mean CV% Um SDPA Exc.

+2

All Methods 5511 584.649 5.1 0.40 38.30 474

Uricase perox. no ascorb. ox. 2319 579.445 5.9 0.80 38.00 231 +11

Standard Deviation
Biosystems A25 15 594.035 4.7 9.00 39.00 1
0

-1
Your Result 565.000 SDI -0.74
RMSDI Too Few
-2

Mean for Comparison 594.035 TS 84

RMTS Too Few <-3

N N N N N N N N N N N N N N 6 N N 9 N 11

%DEV -4.9 Sample Number

RM%DEV Too Few TDPA = 10.8%

120

110

100

Acceptable limits derived from Biological Variation N/A 90

Acceptable limits of performance for RIQAS 10.80 % 80

70

Target Score
60

50

40

30

20

10

N N N N N N N N N N N N N N 6 N N 9 N 11

Sample Number
800

>= 15
700

10
600
Number of Laboratories

500 5
% Deviation

400
0

300
-5

200

-10

100

<= -15

0 N N N N N N N N N N N N N N 6 N N 9 N 11
Sample Number
< 506.94 529.14 551.34 573.54 595.74 617.94 640.14 662.34 >
umol/l
>= 15

Method N Mean CV% Um 10

Uricase perox. no ascorb. ox. 2319 579.445 5.9 0.80

Uricase Perox. with ascorb. ox 1641 592.533 4.2 0.70 5

Uricase Perox. with ascorb. ox @ 546nm 972 582.695 3.9 0.90

% Deviation

Uricase @ 293 nm 154 593.975 1.8 1.00

Ortho Vitros MicroSlide Systems 160 552.938 3.2 1.70 0

Uricase, catalase 340nm. 132 594.543 2.4 1.50

Other Dry Chemistry 24 614.937 5.9 9.30
Agappe - URICASE - TOPS 19 573.470 5.9 9.60 -5

Agappe - URICASE - PAP 19 600.313 7.5 12.80

Reduction methods 15 602.249 4.6 8.90
Vitros DT60/DT60 II 3 559.133 3.4 13.70 -10

<= -15

100 200 300 400 500 600 700

Concentration

Issue No: 1 Issue Date: 03/12/2020 Page 9

A A
MONTHLY CLINICAL CHEMISTRY LABORATORY REF. NO. 520804/A CYCLE 17 SAMPLE 11 30/11/2020

Mean for Your

Analyte Comparison Result SDI RMSDI %DEV RM%DEV TS RMTS Performance

ALT (GPT) 139.515 153.000 1.04 Too Few 9.7 Too Few 70 Too Few
AST (GOT) 163.917 148.000 -1.10 Too Few -9.7 Too Few 67 Too Few
Cholesterol 7.158 7.080 -0.20 Too Few -1.1 Too Few 120 Too Few
Creatinine 0.354 10.945 396.59 Too Few 999.0 Too Few 10 Too Few
Glucose 14.983 14.300 -0.91 Too Few -4.6 Too Few 75 Too Few
Trig Total 247.203 2.750 -12.14 Too Few -98.9 Too Few 10 Too Few
Urea 17.280 16.600 -0.54 Too Few -3.9 Too Few 98 Too Few
Uric Acid (Urate) 594.035 565.000 -0.74 Too Few -4.9 Too Few 84 Too Few

ORMSDI N/A ORM%DEV N/A ORMTS N/A

A
END OF REPORT

Issue No: 1 Issue Date: 03/12/2020 Page 10

A